Am J Transplant, Volume 5, Suppl 3 Archives - Page 158 of 170 - ATC Abstracts

2015 American Transplant Congress
mTOR-Based CNI Minimization Vs Withdrawal in African American Kidney Transplant Recipients
J. Fleming,¹ D. Taber,² N. Pilch,¹ H. Meadows,¹ C. Mardis,¹ J. McGillicuddy,² S. Nadig,² K. Chavin,² P. Baliga,² C. Bratton.²
¹Pharmacy, Medical University of South Carolina, Charleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC.
The purpose of this study was to compare mTOR-based CNI withdrawal vs. minimization in African American (AA) kidney transplant (KTx) recipients.METHODS: This was a single-center,…
2015 American Transplant Congress
A Noninvasive Diagnostic Test of Renal Allograft Rejection Using Urinary-Cell mRNA: A Comparison of Droplet Digital and Real-Time PCR
J.-W. Seo, H. Moon, A. Lee, Y.-W. Choi, Y. Kim, J.-Y. Moon, S.-H. Lee.
Division of Nephrology, Department on Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Background: The diagnosis of acute rejection in kidney transplantation is still standardized by an invasive renal biopsy. Noninvasive tests and biomarkers that can replace the…
2015 American Transplant Congress
Liver Transplantation for Primary Liver Malignancies Vs. Neuroendocrine Metastases: Analysis of the UNOS Dataset
V. Vilchez,¹ M. Shah,¹ M. Daily,¹ S. Krohmer,² D. Davenport,¹ E. Maynard,¹ R. Gedaly.¹
¹Department of Surgery - Transplant Section, University of Kentucky, Lexington, KY; ²Department of Radiology, University of Kentucky, Lexington, KY.
Objective: To determine outcome in patients undergoing LT for NETs, and compared them with outcomes in patients with primary liver malignancies such as Hepatocellular Carcinoma…
2015 American Transplant Congress
Association Between Polymorphisms of PPM1E Gene and Tumor Size of Hepatocellular Carcinoma Patients
M.-S. Park,¹ S.-K. Kim.²
¹Surgery, Kyung Hee University Hospital, Seoul, Korea; ²Pharmacology, Kyung Hee University, Seoul, Korea.
The protein phosphatase, Mg2+/Mn2+ dependent, 1E (PPM1E) inactivates multiple substrates including 5'-AMP activate protein kinases (AMPK) which inhibits the growth and survival of cancer cells.…
2015 American Transplant Congress
Risk Factors for Graft Loss in Pediatric Renal Transplant Recipients After Transfer of Care
B. Coyne,^1,2 P. Hollen,^1,2 Y. Guofen,³ K. Brayman.⁴
¹Department of Pediatrics, University of Virginia Health System, Charlottesville, VA; ²School of Nursing, University of Virginia, Charlottesville, VA; ³Department of Public Health Sciences, University of Virginia Health System, Charlottesville, VA; ⁴Department of Surgery, University of Virginia Health System, Charlottesville, VA.
Improvements in immunosuppression and transplant surgical technique have increased the survival of children with end-stage renal disease. These patients have complex needs, and the current…
2015 American Transplant Congress
The Impact of Ureteral Complications After Pediatric Renal Transplantation
J. Finkelstein,¹ J. Pak,¹ N. Jain,¹ P. Sandoval,² S. Alam.¹
¹Pediatric Urology/Nephrology, Morgan Stanley Children's Hospital, New York, NY; ²Surgery, Columbia University College of Physicians & Surgeons, New York, NY.
Introduction: The incidence of acute renal allograft rejection has declined with advances in immunosuppression, making the evaluation of other risk factors for graft failure vital.…
2015 American Transplant Congress
Electronic Health Service to Improve Therapeutic Drug Monitoring of Immunosuppressants
M. Barten,¹ J. Garbade,² I. Hausladen,² F. Mohr.²
¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Cardiac Surgery, University Leipzig Heart Center, Leipzig, Germany.
PurposeTherapeutic drug monitoring (TDM) of immunosuppressants is critical to avoid rejection or toxic side effects by under- or over-immunosuppression after heart transplantation (HTx). Hence, in…
2015 American Transplant Congress
Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation
F. Liou, M. Kittleson, J. Patel, S. Siddiqui, M. Luu, B. Kearney, D. Ramzy, D. Chang, L. Czer, N. Reinsmoen, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The development of donor-specific antibodies (DSA) after heart transplant has been correlated to the subsequent development of graft rejection. The development of DSA are…
2015 American Transplant Congress
Geographic Differences in HIV+ Kidney Transplant Waitlist Characteristics
J. Locke,¹ S. Gustafson,² C. Durand,³ J. Snyder,² B. Shelton,¹ R. Reed,¹ P. MacLennan,¹ S. Mehta,¹ A. Nellore,¹ D. Segev.^2,3
¹University of Alabama, Birmingham, Birmingham, AL; ²SRTR, MMRF, Minneapolis, MN; ³Johns Hopkins University, Baltimore, MD.
Kidney transplant (KT) is now a viable option for select HIV+ end-stage renal disease (ESRD) patients. As OPTN does not collect HIV status at waitlisting,…
2015 American Transplant Congress
Stem Cell and Novel Biologic Therapies to Enhance Functional Recovery in Limb Transplantation
K. Kniery, M. DeHart, T. Brown, S. Salgar.
Surgery/Clinical Investigation, Madigan Army Medical Center, Tacoma, WA.
Introduction: Unlike visceral organ transplants, vascular composite allotransplantation such as limb and face require successful nerve regeneration and reinnervation of graft motor and sensory targets…